Brain Trust
Global Network = Global Treatment
The MEF2C Brain Trust
Our therapeutic development strategy is guided by our Brain Trust of MEF2C focused scientists, academics, clinicians, consultants, and subject-matter experts who are helping us identify, develop and seed research for therapeutic candidates. As we navigate this journey, we rely on our Brain Trust to apply their collective expertise to navigate the challenges of the therapeutic development and clinical readiness process. Meet some of our team below.
Principal Team
-
Dr. Christopher Cowan
Chair, Department of Neuroscience
Medical University of South Carolina -
Dr. Zachary Grinspan
Chief, Child Neurology
Weill Cornell School of Medicine -
Dr. Margaret Elizabeth Ross
Professor of Neurology
Weill Cornell Medical College
Advisors and Consulting Experts
-
Dr. Huda Zoghbi
Professor in the Departments of Pediatrics, Molecular and Human Genetics
Baylor College of Medicine. -
Dr. Ricardo Dolmetsch
President, Tempero Bio
Adjunct Professor of Neurobiology, Stanford University -
Dr. Eric Olson
Founding Chair, Department Molecular Biology
Distinguished Chair, Stem Cell Research
UT Southwestern -
Cat Lutz
Vice President, Rare Disease Translational Center, Jackson Institute
Global reach, global network
Recognizing the international impact of MCHS, Rare Bird embraces a global vision of MEF2C therapeutic development while leveraging our U.S. presence and expert team to advance our mission.
We partner with our colleagues at MEF2C non-profits worldwide to ensure that the needs of our global population are at the forefront of what we do.
Our clinical readiness, clinical trial, and regulatory efforts are focused on maximizing reach, involvement, and inclusivity.